Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services
Cartherics and Catalent Expand Commercial License Agreement
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Lisata Therapeutics inks global product license deal with Catalent
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
Asia-Pacific Pharmaceutical CMO Market Share Analysis, Trends and Growth Forecasts to 2030 Featuring Catalent, Recipharm, Jubilant Life Sciences and More
Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI
Lisata Therapeutics signs research license with Catalent
Lisata Therapeutics Announces Research License with Catalent
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
Novo Holdings completes $16.5 bln takeover of Catalent
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?
EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
Roche comes out against clearing takeover of drug manufacturer Catalent
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Consumer groups ask FTC to block Novo Holdings-Catalent deal
Catalent Stock Flat Following the Sell Agreement With Ardena
Catalent to sell New Jersey facility
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
More Interest Rate Cuts Ahead: 5 Growth Stocks to Benefit
TAK or CTLT: Which Is the Better Value Stock Right Now?
Catalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
Catalent delays filing of annual report
Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up
Catalent (CTLT) Tops Q4 Earnings and Revenue Estimates
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent